Striking lung cancer response to self-administration of cannabidiol: A case report and literature review.
Josep Sulé-SusoNick A WatsonDaniel G van PittiusApurna JegannathenPublished in: SAGE open medical case reports (2019)
In spite of new drugs, lung cancer is associated with a very poor prognosis. While targeted therapies are improving outcomes, it is not uncommon for many patients to have only a partial response, and relapse during follow-up. Thus, new drugs or re-evaluation of existing therapies used to treat other non-malignant diseases (drug repurposing) are still needed. While this research both in vitro and in vivo is being carried out, it is important to be attentive to patients where the disease responds to treatments not considered standard in clinical practice. We report here a patient with adenocarcinoma of the lung who, after declining chemotherapy and radiotherapy, presented with tumour response following self-administration of cannabidiol, a non-psychoactive compound present in Cannabis sativa. Prior work has shown that cannabidiol may have anti-neoplastic properties and enhance the immune response to cancer. The data presented here indicate that cannabidiol might have led to a striking response in a patient with lung cancer.
Keyphrases
- poor prognosis
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- locally advanced
- long non coding rna
- early stage
- peritoneal dialysis
- squamous cell carcinoma
- case report
- young adults
- patient reported outcomes
- metabolic syndrome
- adipose tissue
- rectal cancer
- weight loss
- patient reported
- squamous cell